DERMAPAM
ActiveSummary
DERMAPAM has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €150,732 and a net result of €57,415. Equity is growing by about 92% per year across the filed financial years. The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
07-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Highest result from 2021 to 2025net €57,415 ▲40.4%
Operating result €90,891, net result €57,415, both a record.
31-12
Financial
Equity above €150,000equity €150,732 ▲61.5%
A profit in every financial year since 2021 builds equity to €150,732.
27-06
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
29-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Liquidity more than triplescurrent ratio 2.24
Current ratio from 0.68 to 2.24; short-term debt falls from €25,980 to €25,765.
17-08
NBB filing
Annual accounts filed
financial year 2022 · micro format · 17 days late
2022
15-07
NBB filing
Annual accounts filed
financial year 2021 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.